90 related articles for article (PubMed ID: 26403972)
1. Identification of the determinants of 2-deoxyglucose sensitivity in cancer cells by shRNA library screening.
Kobayashi H; Nishimura H; Matsumoto K; Yoshida M
Biochem Biophys Res Commun; 2015 Nov; 467(1):121-7. PubMed ID: 26403972
[TBL] [Abstract][Full Text] [Related]
2. 2-Deoxyglucose induces the expression of thioredoxin interacting protein (TXNIP) by increasing O-GlcNAcylation - Implications for targeting the Warburg effect in cancer cells.
Hong SY; Hagen T
Biochem Biophys Res Commun; 2015 Oct; 465(4):838-44. PubMed ID: 26315267
[TBL] [Abstract][Full Text] [Related]
3. New Atglistatin closely related analogues: Synthesis and structure-activity relationship towards adipose triglyceride lipase inhibition.
Roy PP; D'Souza K; Cuperlovic-Culf M; Kienesberger PC; Touaibia M
Eur J Med Chem; 2016 Aug; 118():290-8. PubMed ID: 27155760
[TBL] [Abstract][Full Text] [Related]
4. The reduction of lipid-sourced energy production caused by ATGL inhibition cannot be compensated by activation of HSL, autophagy, and utilization of other nutrients in fish.
Han SL; Liu Y; Limbu SM; Chen LQ; Zhang ML; Du ZY
Fish Physiol Biochem; 2021 Feb; 47(1):173-188. PubMed ID: 33245450
[TBL] [Abstract][Full Text] [Related]
5. Adipose triglyceride lipase regulates lipid metabolism in dairy goat mammary epithelial cells.
Li J; Luo J; Wang H; Shi H; Zhu J; Sun Y; Yu K; Yao D
Gene; 2015 Jan; 554(1):125-30. PubMed ID: 25307872
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of thioredoxin-1 enhances the toxicity of glycolysis inhibitor 2-deoxyglucose by downregulating SLC1A5 expression in colorectal cancer cells.
Tang T; Fang D; Ji Z; Zhong Z; Zhou B; Ye L; Jiang L; Sun X
Cell Oncol (Dordr); 2024 Apr; 47(2):607-621. PubMed ID: 37867183
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of Atglistatin derivatives as adipose triglyceride lipase inhibitors.
Jin J; Huang S; Wang L; Leng Y; Lu W
Chem Biol Drug Des; 2017 Dec; 90(6):1122-1133. PubMed ID: 28548386
[TBL] [Abstract][Full Text] [Related]
8. Atglistatin ameliorates functional decline in heart failure via adipocyte-specific inhibition of adipose triglyceride lipase.
Parajuli N; Takahara S; Matsumura N; Kim TT; Ferdaoussi M; Migglautsch AK; Zechner R; Breinbauer R; Kershaw EE; Dyck JRB
Am J Physiol Heart Circ Physiol; 2018 Oct; 315(4):H879-H884. PubMed ID: 29932770
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel cancer therapeutic targets using a designed and pooled shRNA library screen.
Oliver D; Ji H; Liu P; Gasparian A; Gardiner E; Lee S; Zenteno A; Perinskaya LO; Chen M; Buckhaults P; Broude E; Wyatt MD; Valafar H; Peña E; Shtutman M
Sci Rep; 2017 Feb; 7():43023. PubMed ID: 28223711
[TBL] [Abstract][Full Text] [Related]
10. Aldo-keto reductases-mediated cytotoxicity of 2-deoxyglucose: A novel anticancer mechanism.
Zhang SQ; Yung KK; Chung SK; Chung SS
Cancer Sci; 2018 Jun; 109(6):1970-1980. PubMed ID: 29617059
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationship studies for the development of inhibitors of murine adipose triglyceride lipase (ATGL).
Mayer N; Schweiger M; Fuchs E; Migglautsch AK; Doler C; Grabner GF; Romauch M; Melcher MC; Zechner R; Zimmermann R; Breinbauer R
Bioorg Med Chem; 2020 Aug; 28(16):115610. PubMed ID: 32690265
[TBL] [Abstract][Full Text] [Related]
12. 2-Deoxyglucose induces cell cycle arrest and apoptosisin colorectal cancer cells independent of its glycolysis inhibition.
Muley P; Olinger A; Tummala H
Nutr Cancer; 2015; 67(3):514-22. PubMed ID: 25751508
[TBL] [Abstract][Full Text] [Related]
13. Targeting cisplatin-resistant human tumor cells with metabolic inhibitors.
Sullivan EJ; Kurtoglu M; Brenneman R; Liu H; Lampidis TJ
Cancer Chemother Pharmacol; 2014 Feb; 73(2):417-27. PubMed ID: 24352250
[TBL] [Abstract][Full Text] [Related]
14. Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells.
Ben Sahra I; Laurent K; Giuliano S; Larbret F; Ponzio G; Gounon P; Le Marchand-Brustel Y; Giorgetti-Peraldi S; Cormont M; Bertolotto C; Deckert M; Auberger P; Tanti JF; Bost F
Cancer Res; 2010 Mar; 70(6):2465-75. PubMed ID: 20215500
[TBL] [Abstract][Full Text] [Related]
15. Enhancing the efficacy of glycolytic blockade in cancer cells
Wilson JJ; Chow KH; Labrie NJ; Branca JA; Sproule TJ; Perkins BRA; Wolf EE; Costa M; Stafford G; Rosales C; Mills KD; Roopenian DC; Hasham MG
Cancer Biol Ther; 2019; 20(2):169-182. PubMed ID: 30183475
[TBL] [Abstract][Full Text] [Related]
16. The induction of HAD-like phosphatases by multiple signaling pathways confers resistance to the metabolic inhibitor 2-deoxyglucose.
Defenouillère Q; Verraes A; Laussel C; Friedrich A; Schacherer J; Léon S
Sci Signal; 2019 Sep; 12(597):. PubMed ID: 31481524
[TBL] [Abstract][Full Text] [Related]
17. 2-deoxy D-glucose prevents cell surface expression of NKG2D ligands through inhibition of N-linked glycosylation.
Andresen L; Skovbakke SL; Persson G; Hagemann-Jensen M; Hansen KA; Jensen H; Skov S
J Immunol; 2012 Feb; 188(4):1847-55. PubMed ID: 22227571
[TBL] [Abstract][Full Text] [Related]
18. Development of small-molecule inhibitors targeting adipose triglyceride lipase.
Mayer N; Schweiger M; Romauch M; Grabner GF; Eichmann TO; Fuchs E; Ivkovic J; Heier C; Mrak I; Lass A; Höfler G; Fledelius C; Zechner R; Zimmermann R; Breinbauer R
Nat Chem Biol; 2013 Dec; 9(12):785-7. PubMed ID: 24096302
[TBL] [Abstract][Full Text] [Related]
19. Potentiation of chemotherapeutic drugs by energy metabolism inhibitors 2-deoxyglucose and etomoxir.
Hernlund E; Ihrlund LS; Khan O; Ates YO; Linder S; Panaretakis T; Shoshan MC
Int J Cancer; 2008 Jul; 123(2):476-483. PubMed ID: 18452174
[TBL] [Abstract][Full Text] [Related]
20. Effects of 2-deoxyglucose on drug-sensitive and drug-resistant human breast cancer cells: toxicity and magnetic resonance spectroscopy studies of metabolism.
Kaplan O; Navon G; Lyon RC; Faustino PJ; Straka EJ; Cohen JS
Cancer Res; 1990 Feb; 50(3):544-51. PubMed ID: 2297696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
